Trevena, Inc. (TRVN:OTC) closed at $0.001 on October 20, 2026, unchanged on the day. The stock trades 100.0% below its 52-week high of $1.50 and 66.7% above its 52-week low of $0.000. Trevena, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.
Find more stocks like TRVN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.